Red Glead Discovery has set emissions reduction targets through the Science Based Targets initiative (SBTi), with levels required to meet the goals of the Paris Agreement
Lund, Sweden August 30th, 2022
Red Glead Discovery has set emissions reduction targets through the Science Based Targets initiative (SBTi), with levels required to meet the goals of the Paris Agreement.
Red Glead Discovery has now joined the more than 1600 companies with science-based targets that are in line with the Paris Agreement goals and approved by the SBTi. The approval is a significant milestone for Red Glead Discovery on its transformative, long-term journey for sustainable development in drug discovery.
Climate change, caused by greenhouse gas (GHG) emissions and leading to a rise in global temperature, is one of humanities´ greatest challenge. By setting science-based targets, Red Glead Discovery responds to communications by the Intergovernmental Panel on Climate Change (IPCC), which emphasizes that cutting global emissions in half by 2030 and reaching net zero 2050, can halt, and possibly reverse, the rise in temperatures, mitigating negative effects of climate change.
The SBTi has approved Red Glead Discovery’s near-term science-based emissions reduction target, which means reducing absolute Scope 1 and 2 GHG emissions by 38% by 2030 from a 2021 base year. Red Glead Discovery has also committed to set long-term emissions reduction targets with the SBTi in line with reaching net-zero by 2050 (disclosed at www.sciencebasedtargets.org).
Besides climate action initiatives, Red Glead Discovery has invested in several projects that aim at advancing sustainability in its operations, such as employing green chemistry and artificial intelligence for peptide and small molecule drug discovery. By providing integrated drug discovery services, the company has delivered several small molecule candidate drugs for progress to clinical trials in CNS and cancer indications to clients. The integration of sustainability targets aligned to the UN sustainable development goals (UN SDGs) will enable the company to better respond to future client needs.
Johan Evenäs, CEO Red Glead Discovery AB says: “Setting targets for the reduction of carbon emissions is a logical step for supporting our strategy to become a leading and sustainable European drug discovery company. In the future, our service platform will be increasingly attractive for customers that want to reduce their emissions in the GHG scope 3 part of the value chain.”
Martina Kvist Reimer, Head of Future Business at Red Glead Discovery, states: “The measurement, management, and disclosure of GHG emission data is not only an integral part for enabling reduction of negative climate impact, but also an increasingly important part of standard business practice. Development in line with the UN SDGs is the key ambition the global community has today. To recognise the importance of stewardship for a sustainable future and integrate it into our companies´ DNA, will not only benefit our present clients but also future generations.”
About Red Glead Discovery AB
Red Glead Discovery is a leading Scandinavian provider for integrated drug discovery contract research and supports customers in the Life Science industry to develop their ideas for new drugs. Red Glead Discovery encourages stakeholders to align with climate science by committing to science-based 1.5°C and net-zero targets, and to collaborate for the UN SDGs. For more information on our sustainability initiatives and targets, see www.redglead.com/about/sustainability/
Contact: Martina Kvist Reimer, +46–46-4601292, firstname.lastname@example.org
 The SBTi, a collaboration between the Carbon Disclosure project (CDP), the United Nations GlobalCompact, World Resources Institute and the World Wide Fund for Nature, is a global body enabling businesses to set ambitious emissions reductions targets in line with the latest climate science. It is focused on accelerating companies across the world to halve emissions before 2030 and achieve net-zero emissions before 2050.